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The two main types of diabetes mellitus have distinct etiologies, yet a similar outcome:
loss of islet β-cell function that is solely responsible for the secretion of the insulin hormone
to reduce elevated plasma glucose toward euglycemic levels. Type 1 diabetes (T1D)
has traditionally been characterized by autoimmune-mediated β-cell death leading to
insulin-dependence, whereas type 2 diabetes (T2D) has hallmarks of peripheral insulin
resistance, β-cell dysfunction, and cell death. However, a growing body of evidence
suggests that, especially during T2D, key components of β-cell failure involves: (1) loss
of cell identity, specifically proteins associated with mature cell function (e.g., insulin and
transcription factors like MAFA, PDX1, and NKX6.1), as well as (2) de-differentiation,
defined by regression to a progenitor or stem cell-like state. New technologies have
allowed the field to compare islet cell characteristics from normal human donors
to those under pathophysiological conditions by single cell RNA-Sequencing and
through epigenetic analysis. This has revealed a remarkable level of heterogeneity
among histologically defined “insulin-positive” β-cells. These results not only suggest
that these β-cell subsets have different responses to insulin secretagogues, but that
defining their unique gene expression and epigenetic modification profiles will offer
opportunities to develop cellular therapeutics to enrich/maintain certain subsets for
correcting pathological glucose levels. In this review, we will summarize the recent
literature describing how β-cell heterogeneity and plasticity may be influenced in T2D,
and various possible avenues of therapeutic intervention.
Keywords: diabetes mellitus, type 2, β-cell, dedifferentiation, trans-differentiation, epigenetics, transcription
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INTRODUCTION
Over the past three decades, diabetes mellitus has become a worldwide epidemic, with health-
care and economic burdens climbing dramatically (Ashcroft and Rorsman, 2012; Guariguata
et al., 2014). At the epicenter of diabetes is the β-cell, the most prevalent cell type within the
islets of Langerhans, and the only insulin-producing cell in the body, with the actions of this
hormone essential for lowering blood glucose levels to maintain euglycemia. T1D results in
insulin-dependency after autoimmune mediated β-cell destruction, whereas the more prevalent
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T2D is a complex metabolic disorder resulting from insulin
resistance and progressive β-cell inactivation. Regardless of
etiology, both forms of diabetes are underpinned by loss
of glucose stimulated insulin secretion and concomitant
hyperglycemia. In the setting of T2D progression, prolonged
elevation in glucose and/or fatty acid levels leads to a failure
of β-cell insulin production, and secretion, potentially followed
by reduced cell survival; this condition is termed as gluco-
lipotoxicity (reviewed in Poitout et al., 2010).
Although islet β-cell death is a clear outcome in T1D, recent
evidence points to more complex mechanisms that affect β-
cell identity and function in T2D. A change in identity is
defined as reduced expression of proteins or functional changes
essential to a cell type, which in this case includes insulin
and essential β-cell-enriched transcription factors. This contrasts
from de-differentiation, wherein the β-cell is converted into
earlier progenitor state, which in rodent models can included
loss of insulin expression and gain of Neurogenin 3 (i.e., Ngn3)
and Nanog transcription factor production. For example, it was
generally believed that the obesity and insulin resistance stress
conditions associated with T2D led to islet β-cell failure cell
death and reduced insulin+ cell mass. However, we will discuss
growing evidence suggesting that, as T2D progresses, β-cells do
not die, but lose insulin expression, possibly de-differentiating
toward a progenitor state, and then into other islet cell types. At
a minimum, there is evidence for loss of β-cell identity during
the course of the disease (a topic recently reviewed in Brereton
et al., 2016). Although less convincing, there is also evidence for
altered endocrine identity during T1D. Here, we will assess the
latest reports regarding β-cell heterogeneity, which collectively
suggest that there are islet insulin+ cell populations with varying
functionality and signature marker expression levels.We will also
discuss how the paradigms of β-cell life and death during T2D
have changed in recent years to include greater appreciation for
cellular identity and plasticity.
ISLET β-CELL IDENTITY AND
HETEROGENEITY
In a classic sense, β-cells have been defined by insulin expression
and controlled secretion under high glucose conditions. Indeed,
one might refine the definition to also include the requisite
expression of key β-cell transcriptional regulators, for example
MafA, Nkx6.1, and Pdx1 (Guo et al., 2013; Schaffer et al., 2013;
Gao et al., 2014), as well as the cellular machinery responsible
for glucose-stimulated insulin secretion (e.g., Glut2, Gck, Kcnj11)
(Prentki et al., 2013). However, several lines of evidence now
challenge us to further modify this definition. New technologies,
including single-cell transcriptomics and mass cytometry, have
allowed the field to “drill deeper” into the β-cell mass to more
definitively reveal the long-suspected heterogeneity within the
insulin+ population (Salomon and Meda, 1986; Pipeleers, 1992;
Van Schravendijk et al., 1992), especially across species and in
non-diabetic vs. T2D donors (Segerstolpe et al., 2016;Wang et al.,
2016a,b; Xin et al., 2016). Several recent resource publications
shared the single cell transcriptomes of human islet cells under
diabetic and non-diabetic conditions (Segerstolpe et al., 2016;
Wang et al., 2016b; Xin et al., 2016).
Segerstolpe et al. utilized single-cell RNA-Sequencing profiling
to identify five clusters of insulin+ cells, two of which had
varying levels of RBP4 and FFAR4 expression, encoding proteins
impacting insulin resistance and release, respectively (Segerstolpe
et al., 2016). Further, this study identified genes that were
dysregulated in non-diabetic vs. T2D β-cells. FXYD2 (encoding a
Na/K-ATPase subunit) was the most significantly downregulated
gene in T2D β-cells, which can influence glucose tolerance and
insulin levels in mice (Arystarkhova et al., 2013). Conversely,
GPD2 (involved in mitochondrial metabolism) and LEPROTL1
(also called endospanin-2, impacts localization of the leptin
and GH receptors) were upregulated. Wang et al. compared
single-cell transcriptomes across non-diseased, T1D, T2D, and
juvenile human islet samples. Interestingly, β-cell gene signatures
of adult T2D samples were less defined than in non-diseased
adults, with resemblance to less mature juvenile cells (Wang
et al., 2016b). These data demonstrate that β-cell gene expression
differences exist between healthy and T2D populations. However,
it is unclear precisely what the defining functional molecular
signatures are, due to the early and limited nature of these studies.
It is appreciated that islet β-cells have distinct subtypemarkers
within normal and T2D populations. Rat β-cells with increased
insulin secretion capacity were found to express higher levels of
PSA-NCAM (a cell adhesion molecule) and CDH1/E-Cadherin
(Bernard-Kargar et al., 2001; Bosco et al., 2007), whereas human
cells express variable levels of VMAT2 (encoding a monoamine
transporter) and DKK3 (encoding a Wnt signaling modulator)
(Hermann et al., 2007; Saisho et al., 2008). More recently, Dorrell
et al. utilized cell-surface recognizing antibodies to reveal that
human β-cells can be sub-divided into four sub-types (i.e., β1–
β4) based upon ST8SIA1 (a ganglioside synthase) and CD9 (a
cell surface glycoprotein) levels (Dorrell et al., 2016) (Figure 1).
These subtypes had both variable abundance (e.g., β1 > β4)
and insulin secretion activity (i.e., β1 > β2–4) under normal
conditions. Moreover, the less glucose-responsive β3–β4 cell
populations also appeared to become more prevalent in T2D
islet samples, presumably representing a state of compromised β-
cell activity. In addition, islet β-cell heterogeneity was observed
in mouse cell subpopulations due to expression of Flattop
(Fltp), a Wnt/PCP effector gene (Bader et al., 2016). Using
a Fltp knock-in reporter mouse line (i.e., FVR), Bader et al.
found temporal increases in expression, such that 80% of adult
Nkx6.1+ β-cells were Fltp+, arising from more proliferative
FVR− precursor β-cells. Through cell sorting and comparative
mRNA expression and functional profiling, it was proposed
that Fltp+ (FVR+) cells represent a mature β-cell population,
with characteristically high insulin levels, enrichedmitochondrial
activity, elevated metabolic function, and expression of defining
cell gene expression signatures. However, Fltp knockout mice
(i.e., FltpZV/ZV ) had only small, albeit significant defects in fasting
blood glucose and plasma insulin levels (Bader et al., 2016),
implying that Fltp is a key marker, but not a determinant of
mature β-cells.
A newly defined biomarker of “failing” T2D cells appears
to involve induction of aldehyde dehydrogenase 1 isoform
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FIGURE 1 | Model depicting both endocrine progenitor differentiation into a heterogeneous population of β-cells within human islets, and potential
pathways of cell inactivation recently described in T2D. Inactivation likely involves mechanisms that result in loss/reduction β-cell identity marker expression
(e.g., MafA, Nkx6.1, Pdx1, insulin) as well induction of cell failure signatures (e.g., ALDH1A3; Kim-Muller et al., 2016). β1–4 cells represent at least some of the
functionally distinct β-cell populations in human islets, with our model suggesting that failing T2D islets will be composed of several (e.g., β3 and β4; Dorrell et al.,
2016). In addition, there is evidence in (at least) mouse islets that failing β-cells can de-differentiate to progenitor-like cells expressing Ngn3, Nanog, L-Myc, and Oct4
(Talchai et al., 2012).
A3 (ALDH1A3) (Kim-Muller et al., 2016). Thus, upregulated
ALDH1A3 levels (normally only produced in progenitors
during embryogenesis) were observed in adult islet β-cells
from FoxO (1, 3a, 4) triple knockout mice, and also found
in the dysfunctional β-cell populations in db/db, Nkx6.1, and
MafA-deficient mouse models (Taylor et al., 2013; Hang et al.,
2014; Kim-Muller et al., 2016). Sorted ALDH1A3+ cells were
less glucose responsive than cells lacking ALDH1A3, had
reduced levels of mature β-cell markers (e.g., Glucokinase,
MafA), concomitant increases in progenitor markers (e.g.,
Rfx6, Rfx7, Mlxipl), and mitochondrial dysfunction (Kim-
Muller et al., 2016). Although still unclear, some evidence
suggests that ALDH1A3 also does not directly cause β-cell
dysfunction.
Interestingly, Johnston et al. have revealed another level of
islet β-cell heterogeneity upon identifying “hub” β-cells (i.e.,
∼1–10% of the islet cells) that exert a disproportionate control
on the broader β-cell “follower” population (Johnston et al.,
2016). The mouse hub cells are intermingled with other islet
β-cells but have reduced marks of β-cell maturity, including
lower insulin content, reduced Pdx1, and nearly absent Nkx6.1.
Using targeted cell laser illumination methods, the hub cells
were shown to be essential to glucose-induced Ca2+ signaling,
and by extension, insulin secretion. (Technical limitations
precluded directly analyzing islet insulin secretion levels.)
Strikingly, incubating islets in a proinflammatory cytokine
cocktail (IL-1β, IL-6, TNFα) impaired hub cell number, providing
evidence that the diabetic milieu would compromise islet
secretion dynamics. However, the molecular and functional
properties of human islet hub cells are still poorly defined
as is their relationship to the many recently defined and
distinct β-cell populations. Collectively, these studies highlight
the heterogeneity of islet β-cells and illustrates how the gluco-
lipotoxic conditions associated with diabetes could influence
their prevalence by changing in β-cell identity or differentiation
states.
ISLET CELL PLASTICITY
Underlying the notion of heterogeneity is whether human islet
cells exist in a fixed, terminally differentiated state or if a level
of cellular plasticity exists. Thus, evidence has been accumulating
from studies in animal models that islet cells have the capacity
to directly trans-differentiate to another islet cell fate and/or
de-differentiate to a progenitor-like cell. The past decade has
revealed in numerous rodent models that various stressors can
impart pancreatic cell reprogramming, although it has been
argued that β-cell replacement by replication is the predominant
mechanism (Dor et al., 2004; Teta et al., 2007). Some
physiological stressors, including pregnancy or obesity, have not
provided clear evidence of islet cell reprogramming (reviewed
in Cigliola et al., 2016). However, it appears that extreme
physical injury, chemical stresses, or genetic perturbations are
able to promote reprogramming (Figure 2). For example, as
a model of pancreatitis, pancreatic duct ligation (PDL) causes
regeneration of islets from Ngn3+ transcription factor islet
endocrine progenitors adjacent to the ductal epithelium (Xu
et al., 2008). This level of regeneration does not speak to the
plasticity of β-cells per se, but highlights how the pancreas (or
resident progenitors) can combat injury.
Significantly, direct α-to-β or β-to-α conversion has been
observed through lineage tracing in several cell-type specific
transcriptional regulator gene deficiency or over-expression
models, including Arx, Pdx1, Pax4, and Dnmt1 (Collombat et al.,
2007, 2009; Dhawan et al., 2011; Yang et al., 2011; Gao et al.,
2014). Cell ablation studies employing β-cell toxins including
diphtheria toxin, streptozotocin, or alloxan, have also been
useful in demonstrating how other islet endocrine cell types can
adopt β-cell fates (Figure 2). For example, the Herrera group
in Switzerland demonstrated that a nearly complete loss of islet
β-cells imposed by directed diphtheria toxin destruction results
in the reprogramming of adult islet α-cell or juvenile islet δ-
cells to a β-cell fate (Thorel et al., 2010; Chera et al., 2014).
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FIGURE 2 | Schematic illustrating the possible outcomes on human
insulin-positive cell production during islet (e.g., α- or δ-cell; Thorel
et al., 2010; Chera et al., 2014) and ES/iPS cell differentiation (Pagliuca
et al., 2014; Rezania et al., 2014). Extensive characterization needs to be
performed on these newly-generated insulin-producing cells to determine their
functional and molecular characteristics in relation to existing human islet β-cell
populations.
Also, administration of the β-cell toxin alloxan in combination
with PDL or the cerulein peptide (an inducer of pancreatitis)
promoted trans-differentiation of α- to β-cells (Chung et al.,
2010; Piran et al., 2014). Collectively, these results demonstrated
that rodent islet cells have the capacity to trans-differentiate and
replace β-cell mass. However, few of these studies have included
comprehensive molecular and functional analysis to determine
how closely reprogramming represents the bona fide islet β-cell
populations.
It is likely that the mechanisms underlying how islet cell types
adopt β-cell-like fates involve epigenetic influences at critical islet
loci. For example, permissive histone and/or DNA modifications
(e.g., methylation) may allow for expression β-cell-specific genes
in α-cells, thus promoting cellular conversion. Bramswig et al.
employed RNA- and ChIP-sequencing in sorted human α- and β-
cells to reveal a remarkable level of α-cell plasticity, by examining
the levels of the activating histone H3K4me3 and repressive
H3K27me3 marks (Bramswig et al., 2013). Surprisingly, α-
cells bear a large number of β-cell genes bivalently marked by
H3K4me3 andH3K27me3, suggesting these genes are in a poised,
inducible state. These included key β-cell functional genes, like
MAFA, PDX1, GLP1R, and PCSK1. Furthermore, treatment of
whole human islets with Adox, a histone methyltransferase
inhibitor that prevents H3K27me3 formation, induced β-cell-
specific PDX1 expression in α-cells. Indeed, ultrastructural
analysis revealed insulin and glucagon granule co-localization in
Adox-treated cells. When jointly considered, these data suggest
that α- (and likely δ-) cells exist in a malleable epigenomic state
that enables conversion to β-like cells in many mouse models
(Collombat et al., 2009; Thorel et al., 2010; Yang et al., 2011), and
potentially in human islets (Bramswig et al., 2013) (Figure 2).
DE-DIFFERENTIATION AND T2D
The apparent heterogeneity of the islet β-cell population and
plasticity of other islet cell types led the field to question what
happens to β-cell identity during the progression to T2D state.
Under conditions of prolonged T2D, β-cells likely die, leading
to reduced β-cell mass, but recent studies suggest that de-
differentiation may also cause loss of insulin+ cell mass. In
this regard, one of the most striking observations came from
Talchai et al. (2012) examining how β-cell fate was affected in
FoxO1-deficient mice under the metabolically challenging and
stressful conditions associated with high fat diet and multiple
pregnancies. Rather than islet β-cell dysfunction and death,
they found that β-cells apparently de-differentiated, as defined
by insulin degranulation, and most significantly, upregulation
of various embryonic progenitor markers (e.g., Ngn3, L-Myc,
Nanog, and Oct4; Talchai et al., 2012) (Figure 1). Work from
the Melton group also revealed that loss of Urocortin 3 (Ucn3),
a mature β-cell marker (Blum et al., 2012), is an early signal of
de-differentiation in diabetic mouse models (e.g., ob/ob, db/db,
Akita) (Blum et al., 2014). Furthermore, the progenitors arising
from the de-differentiated β-cell pool in the Talchai et al. study
(i.e., insulin−/Ngn3+/Oct4+/L-Myc+ cells) were followed by
lineage tracing to reveal their conversion to non-β-cell fates,
including α-, δ, and PP-cells. A similar population of de-
differentiated β-cells were found in other T2D mouse models,
including db/db andGIRKO (Glut4-Cremediated InsR knockout;
Lin et al., 2011) mice. In two other complementary studies,
diabetic mice bearing activating KATP channel mutations lead
to increased expression of Ngn3 and production of insulin−
β-cells (Brereton et al., 2014; Wang et al., 2014). Strikingly,
insulin treatment of these diabetic mice not only restored glucose
homeostasis, but resulted in re-differentiation of the Ngn3+ cells
into insulin+ β-cells. Collectively these studies not only suggest
that a key outcome of T2D is β-cell de-differentiation, but that
the process is reversible (Figure 1).
These reports revealed that de-differentiation and re-
differentiation as mechanisms of islet β-cell failure and
rescue, however the therapeutic importance would only be of
significance if observed in human T2D β-cells. To this end,
evidence for this possibility is unclear or even unsupportive,
which may in part be due to the relatively recent nature of
these observations in mice, but may also reflect differences
between species (Kim et al., 2009; MacDonald et al., 2011;
Dai et al., 2012). Nonetheless, some promising observations
have been reported. White et al. employed immunofluorescence
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examination of three human T2D donor pancreata to reveal
numerous insulin+ cells that co-localized with glucagon or the
vimentin mesenchymal marker (White et al., 2013), suggesting
altered β-cell identity. Accordingly, Spijker et al. found a
significant increase in bihormonal insulin+/glucagon+ and
NKX6.1+/amyloid+/glucagon+ cells upon analyzing mature β-
cell markers (e.g., MAFA, FOXO1, NKX6.1) in human and non-
human primate normal or T2D samples (Spijker et al., 2015).
These “mixed phenotype” cells are consistent with the loss of
β-cell and gain of α-cell characteristics in T2D islets. Similarly,
the Accili group at Columbia University suggested that the
presence of insulin−/synaptophysin+/ALDH1A3+ cells in T2D
islets implies that de-differentiation is occurring under these
conditions (Cinti et al., 2016), although ALDH1A3 could also
be marking dysfunctional islet β-cells. Moreover, the stomach
hormone gastrin, a typical embryonic pancreas marker, was
found to be induced in mouse and human β-cells under
hyperglycemic T2D conditions, a phenomenon that resolves
upon glucose normalization (Dahan et al., 2016).
While the above results indicate that β-cells may
dedifferentiate under T2D conditions, others have argued
that this is minor, or even non-existent. Thus, Butler et al.
recently posited that the hormone-negative chromogranin+ cells
observed in T2D pancreata are not the dedifferentiated β-cells
found in mouse models, but rather immature β-cells arising
during regeneration (Butler et al., 2016). Moreover, while Guo
et al. (2013) found a change in β-cell identity was supported by
the loss in many cell-enriched transcription factors in human
T2D islets, there was no evidence for the increased progenitor
mRNAs expression found in rodent studies, including NGN3,
NANOG, andMYCL1. The human islet single-cell transcriptome
analyses have also failed to reveal compelling evidence for
de-differentiation (Segerstolpe et al., 2016; Xin et al., 2016). It
is very likely that the extensive efforts underway to characterize
normal and T2D human islet populations will soon resolve
how islet β-cell function is compromised in the T2D patients,
and hopefully lead to the development of therapeutics to either
prevent or correct the deficiencies.
CONCLUSIONS AND PERSPECTIVES
The possibility that human T2D β-cells undergo de-
differentiation, trans-differentiation, or (at least) loss of
identity raises several questions about future diabetes therapeutic
strategies. Can we exploit the signals that trigger β-cell de-
differentiation or loss of identity during these processes?
Specifically, can drugs or small molecules be designed to
attenuate the process, or that efficiently and specifically
regenerate functional β-cells? These studies could be similar
to small molecule screens that have revealed that harmine
analogs positively impact human β-cell proliferation (Wang
et al., 2015). Blum et al. also employed an in vivo Ucn3-GFP
reporter and lineage tracing to track the de-differentiation state
of mouse β-cells in the presence of various small molecules
(Blum et al., 2014). A TGFβ pathway inhibitor, Alk5 inhibitor
II, potently restored the GFP signal in islets cultured under
de-differentiation conditions. Further, the compound increased
mRNA levels of key β-cell maturity markers including Ucn3,
MafA, Nkx6.1, and Pdx1. However, much more work needs to
be done to definitively demonstrate whether these mechanisms
are at play in human β-cells. If so, the field should focus on
developing pharmacological reagents that can maintain the
mature, differentiated β-cell, or induce re-differentiation in T2D
patients. Further, there is a need for more extensive studies
revealing the unique properties regulating the activity of the
distinct β-cell populations produced under normal and diabetic
circumstances. Given the notable morphological and functional
differences between rodent and human islets (Kim et al., 2009;
MacDonald et al., 2011; Dai et al., 2012), improved modeling of
the human disease process will also move the field forward. A
recent report from the Powers group at Vanderbilt University
took strides toward addressing this by comparing transplanted
mouse and human islets under gluco- or lipo-toxic conditions,
revealing significant differences in responses between species
(Dai et al., 2016). The ability to lineage trace human islet
cells would also be a major innovation allowing for a better
understanding of the fate of β-cells when exposed to diabetic
stress conditions in vivo. Importantly, recent studies have
brought to the forefront that not all insulin+ cells are equal,
and increasing the mass and/or activity of truly functional (i.e.,
glucose sensing and insulin secreting) β-cells will push the field
closer to a diabetes cure. Moreover, assessing levels of such
heterogeneity markers (e.g., ST8SIA1, CD9, Fltp, ALDH1A3)
during human embryonic stem cell (or induced pluripotent
stem cell) directed β-cell differentiation protocols (Pagliuca
et al., 2014; Rezania et al., 2014) (Figure 2), including cells
currently in clinical trials (Viacyte, clinicaltrials.gov identifier
NCT02239354), will allow for a better evaluation of the integrity,
functionality and reliability of these potential therapeutic
reagents.
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